An industry perspective on drug target validation
نویسندگان
چکیده
منابع مشابه
Microbial Monitoring For Biological Drug Substance Manufacturing: An Industry Perspective.
Diane Hardy, Chief Microbiologist, Regeneron Brian L. Bell, Senior Scientist, Bristol-Myers Squibb Ren-Yo Forng, Site Microbiologist, Astra Zeneca Michael Knight, Senior Manager QC Microbiology, Genentech Anita Bawa, Director QC, Bayer Stephanie Ramsey, Manager Quality Systems, Baxter Christine Arbesser-Rastburg, Director Quality Operations / Microbiology, Baxter Mousumi Paul, Associate Directo...
متن کاملTarget validation: the Parkinson disease perspective.
1Center for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, AL 35294, USA *Author for correspondence ([email protected]) How much validation is enough? Target validation is the process of determining the likelihood that modification of a certain molecule, mechanism or biological pathway may be useful for the development of pharmacological or mo...
متن کاملDrug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development.
It is generally accepted that there is neither a well-defined nor a consistent link between the formation of drug-protein adducts and organ toxicity. Because the potential does exist, however, for these processes to be causally related, the general strategy at Merck Research Laboratories has been to minimize reactive metabolite formation to the extent possible by appropriate structural modifica...
متن کاملTarget validation: A door to drug discovery.
From ancient times to today, drug discovery transitioned from serendipity to rationality over its long history. Proper drug target selection and validation are crucial to the discovery of new drugs. This review discusses the definition of drug targets and proposes several characteristics for drug targets. The limitations of the term 'target' itself are summarized. The drug target validation pro...
متن کاملPeptide deformylase as an antibacterial drug target: target validation and resistance development.
New inhibitors of peptide deformylase (PDF) which are very potent against the isolated enzyme and show a certain degree of antibacterial activity have recently been synthesized by our group. Several lines of experimental evidence indicate that these inhibitors indeed interfere with the target enzyme in the bacterial cell. (i) The inhibition of Escherichia coli growth could be counteracted by ov...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Expert Opinion on Drug Discovery
سال: 2016
ISSN: 1746-0441,1746-045X
DOI: 10.1080/17460441.2016.1182484